ImmunityBio (IBRX) Retained Earnings (2014 - 2026)

ImmunityBio (IBRX) has reported Retained Earnings for 13 consecutive years, with -$4.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 24.38% year-over-year to -$4.4 billion; the TTM figure through Mar 2026 stood at -$4.4 billion (down 24.38% YoY), while the FY2025 annual figure was $29.0 million, up 100.86% from the prior year.
• Retained Earnings retreated to -$4.4 billion in Q1 2026 per IBRX's latest filing, from $29.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $29.0 million in Q4 2025 and bottomed at -$4.4 billion in Q1 2026.
• Historically, Retained Earnings has averaged -$2.3 billion across 5 years, with a median of -$2.6 billion in 2023.
• On a YoY basis, Retained Earnings climbed as much as 100.86% in 2025 and fell as far as 50069814.29% in 2025.
• ImmunityBio's Retained Earnings stood at -$2.4 billion in 2022, then retreated by 24.52% to -$3.0 billion in 2023, then declined by 13.96% to -$3.4 billion in 2024, then soared by 100.86% to $29.0 million in 2025, then tumbled by 15155.35% to -$4.4 billion in 2026.
• Business Quant data shows IBRX's Retained Earnings at -$4.4 billion in Q1 2026, $29.0 million in Q4 2025, and -$3.7 billion in Q3 2025.